The potential first-in-class antisense RNA-based therapy led to sustained clearance of HBsAg and HBV DNA for 24 weeks after treatment ended in the phase 2b study.

Hepatitis B virus, a killer of more than one million people each year, is a notoriously wily virus, often lingering and ...

Novel hepatitis B virus RNA and HBV core-related antigen blood assays revealed continued disease activity despite apparently suppressed virus replication among patients dosed with antiviral ...

Assembly Biosciences, Inc. (NASDAQ:ASMB) is one of the growth stocks that could double by 2027. On June 25, the company ...

Florian van Bömmel ¹, Alena van Bömmel ², Alexander Krauel ¹, Cynthia Wat ³, Vedran Pavlovic ³, Lei Yang ⁴, Danilo Deichsel ¹, Thomas Berg ¹, Stephan Böhm ¹⁵, Serum HBV RNA as a Predictor of ...

Yuen M-F, Wong D K-H, Schluep T, et al. Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. Gut.

Extending dosing of a novel GalNAc-small interfering RNA brought most patients’ surface antigen levels of hepatitis B virus under control, according to a presenter at the International Liver ...

Although clinically, HDV and acute HBV infections present with the same symptoms and characteristics, HDV infection carries a higher risk of acute liver failure, particularly for intravenous drug ...

In a recent paper published in Science Translational Medicine, scientists report that a class of drugs, called RNA interference (RNAi) therapeutics, represent a major advancement in the treatment of ...